Ribosomal protein mutations in Korean patients with Diamond-Blackfan anemia.
- Author:
Hyojin CHAE
1
;
Joonhong PARK
;
Seungok LEE
;
Myungshin KIM
;
Yonggoo KIM
;
Jae Wook LEE
;
Nack Gyun CHUNG
;
Bin CHO
;
Dae Chul JEONG
;
Jiyeon KIM
;
Jung Rok KIM
;
Geon PARK
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: array-CGH; Diamond-Blackfan anemia; ribosomal protein; sequencing
- MeSH: Anemia, Diamond-Blackfan/*genetics; Female; Gene Frequency; Humans; Infant, Newborn; Male; *Mutation; RNA, Messenger/genetics/metabolism; Republic of Korea; Ribosomal Proteins/*genetics/metabolism; Tumor Suppressor Protein p53/genetics/metabolism
- From:Experimental & Molecular Medicine 2014;46(3):e88-
- CountryRepublic of Korea
- Language:English
- Abstract: Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by hypoproliferative anemia, associated physical malformations and a predisposition to cancer. DBA has been associated with mutations and deletions in the large and small ribosomal protein genes, and genetic aberrations have been detected in approximately50-60% of patients. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method. Mutations in RPS19, RPS26 and RPS17 were detected in four, two and one patient, respectively. Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G). For the mutation-negative cases, array-CGH analysis was performed to identify copy-number variations, and no deletions involving the known DBA gene regions were identified. The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients. In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients. Among these patients, RPS19 was the most frequently mutated gene. In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.
